United States Dermatological Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states dermatological drugs market size is expected to grow from USD 16.78 billion in 2025 to USD 18.19 billion in 2026 and is forecast to reach USD 28.30 billion by 2031 at 9.24% CAGR over 2026-2031. This report is Segmented by Indication (Acne, Psoriasis, Atopic Dermatitis, Rosacea, Alopecia Areata, HS, Other), Prescription Status (Prescription, OTC), Route (Topical, Oral, Parenteral), Drug Class (Corticosteroids, Retinoids, Antibiotics, PDE-4 Inhibitors, JAK Inhibitors, Biologics, Other), and Distribution (Hospital, Retail, Online Pharmacies). Market Forecasts are in Value (USD).

United States Dermatological Drugs Market Trends and Insights

Rising Biologic Uptake in Psoriasis

Psoriasis remains the main specialty revenue engine in the United States dermatological drugs market because biologic therapy has moved treatment expectations closer to high skin-clearance outcomes rather than partial disease control. AbbVie reported Skyrizi global revenue of USD 17.6 billion in 2025, which shows how large the commercial psoriasis pool has become for leading immune therapies. Johnson & Johnson also received FDA approval in March 2026 for Icotyde, described as the first oral IL-23R antagonist for plaque psoriasis in adults and adolescents, which adds a meaningful non-injectable option to a class that had been led by subcutaneous biologics. That shift matters because prescribing competition is starting to depend less on basic efficacy differences and more on dosing convenience, patient preference, and whether a brand can hold patients through switching cycles. As penetration matures, the United States dermatological drugs market is likely to see more value migrate through brand switching and line extension rather than through first-time diagnosis alone.

Expanding Moderate-To-Severe Atopic Dermatitis Treatment Pool

Atopic dermatitis has become one of the most important specialty segments in the United States dermatological drugs market because treatment now spans biologics, oral immunomodulators, and newer non-steroidal topicals. Dupixent generated USD 17.8 billion in global net sales in 2025, and Regeneron reported more than 1.4 million patients on treatment globally with first-quarter 2026 sales of USD 4.9 billion, which shows how large and durable this treatment base has become. Sanofi also reported positive Phase 3 data in March 2026 for amlitelimab across the COAST 1, COAST 2, and SHORE trials, which adds another late-stage biologic candidate for moderate-to-severe disease. The category is therefore widening at both ends, with severe disease pulling in high-value specialty biologics and milder disease moving toward more durable non-steroidal topical management. This broader treatment ladder is helping the United States dermatological drugs market expand without depending on a single mechanism or one patient severity band.

High Biologic Prices and Prior-Authorization Friction

Access barriers remain a major brake on the United States dermatological drugs market, even when clinical demand is strong. A JAMA Dermatology analysis available through PMC found that 87% of biologic prescriptions required prior authorization and that a typical dermatology practice faced an average monthly administrative cost of USD 3,454 from this process. That burden means treatment delays are often driven by paperwork and payer review rather than by physician reluctance or lack of patient need. It also pushes practices to spend time on access management that could otherwise support faster initiation or follow-up care. Even with reimbursement reform moving in a favorable direction, prior authorization keeps slowing real conversion in the United States dermatological drugs market.

Other drivers and restraints analyzed in the detailed report include:

• Strong FDA Approval Cadence in Medical Dermatology
• Persistent Acne Burden Sustaining Rx and OTC Demand
• Biosimilar Interchangeability and PBM Switching Friction

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Psoriasis held 33.87% of United States dermatological drugs market share in 2025, which kept it as the largest therapeutic revenue pool in this report. That lead reflects strong biologic penetration and high annual treatment value in moderate-to-severe disease. AbbVie’s Skyrizi posted USD 17.6 billion in global revenue in 2025, which shows how much scale psoriasis-targeted biologics can reach once they become embedded in specialist practice. March 2026 also brought FDA approval for Icotyde as the first oral IL-23R antagonist for plaque psoriasis, adding a non-injectable systemic option that may widen reach among patients reluctant to use injectable therapy. Atopic dermatitis remained the second-largest indication, supported by the continued scale of Dupixent and by a broader pipeline that is widening treatment choice in the United States dermatological drugs industry.

Hidradenitis suppurativa is the fastest-growing indication, with projected growth of 9.97% through 2031, and it stands out because class expansion is starting from a lower commercial base. UCB received FDA approval in November 2024 for Bimzelx in adults with moderate-to-severe hidradenitis suppurativa, introducing the first dual IL-17A and IL-17F inhibitor for the condition, and UCB reported 2025 net sales of EUR 2.2 billion, equivalent to USD 2.4 billion, for the product. Novartis then expanded the treatment pool further in March 2026 with FDA approval of Cosentyx for pediatric patients aged 12 and older with moderate-to-severe hidradenitis suppurativa. Rosacea and fungal skin infections continue to rely more on affordable topical therapy and stable volume, while alopecia areata has become more visible after the arrival of FDA-approved JAK options. The broader “other” group is also gaining relevance, because Dupixent added dermatology-adjacent approvals in chronic spontaneous urticaria and bullous pemphigoid during 2025.

Prescription products accounted for 73.42% of 2025 revenue, which shows how much value is still concentrated in branded specialty therapies and prescription topicals. This part of the United States dermatological drugs market is led by psoriasis, atopic dermatitis, and hidradenitis suppurativa treatments that require specialist evaluation, payer review, or continued clinical monitoring. Prescription demand is also sustained by route complexity, since injectable biologics and monitored oral agents cannot be replaced by self-care in moderate-to-severe disease. Even so, the revenue mix is beginning to shift because OTC products are forecast to grow at 10.06% CAGR through 2031, which is faster than the prescription tier. That faster pace suggests the United States dermatological drugs market is widening through consumer-directed management rather than relying only on high-cost prescription escalation.

The OTC side benefits from several forces moving at the same time, including stronger consumer skincare awareness, easier digital consultation, and better retail and online availability. These factors matter most in acne, mild eczema, and other lower-complexity conditions where patients often start treatment before entering specialist care. Telehealth and digital pharmacy tools also support this shift, because patients can move from symptom review to product recommendation and purchase more quickly than in a traditional office-led pathway. From a payer perspective, OTC migration can reduce reimbursement pressure in categories where outcomes do not always require a covered prescription. The result is a more layered United States dermatological drugs industry, where prescription products keep revenue leadership, but OTC products continue to pull share through convenience and access.

Complete Report Scope:

• By Indication
  • Acne
  • Psoriasis
  • Atopic Dermatitis
  • Rosacea
  • Alopecia Areata
  • Hidradenitis Suppurativa
  • Fungal Skin Infections
  • Other Dermatological Indications
• By Prescription Status
  • Prescription
  • Over-the-Counter
• By Route of Administration
  • Topical
  • Oral
  • Parenteral
• By Drug Class
  • Corticosteroids
  • Retinoids
  • Antibiotics
  • Antifungals
  • Calcineurin Inhibitors
  • PDE-4 Inhibitors
  • JAK Inhibitors
  • Biologics
  • Other Drug Classes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drugstores
  • Online Pharmacies

List of Companies Covered in this Report:

• Abbvie
• Almirall
• Amgen
• Arcutis Biotherapeutics
• Bausch Health
• Bristol-Myers Squibb
• Eli Lilly and Company
• Galderma
• GlaxoSmithKline
• Incyte
• Johnson & Johnson Innovative Medicine
• Leo Pharma
• Novartis
• Organon
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• UCB

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support